Semaglutide for AUD / OUD: BRIDGE Launches at Caron Treatment Centers
15 patients are already receiving semaglutide as part of their treatment program.
CASPR is delighted to announce that the BRIDGE Initiative at Caron Treatment Centers officially began on April 14th. This groundbreaking program is the first of its kind to offer direct access to GLP-1 receptor agonists (GLP-1 RAs) for individuals undergoing residential treatment for substance use disorders.
In just its first week, the BRIDGE program has already enrolled 15 participants at Caron and is integrating GLP-1 RAs along with clinical interventions, behavioral strategies, and 12-step.
“Caron Treatment Centers has long been at the forefront of combining evidence-based medicine with the timeless principles of recovery,” said Steven Klein MD/PhD, a physician at Caron and the leader of the initiative. “Through our collaboration with CASPR on the BRIDGE initiative, we’re proud to carry forward that legacy. This program reflects our shared commitment to innovation, compassion, and comprehensive care—meeting patients where they are and supporting them every step of the way.”
We will keep you updated on news and progress of the program. If you’d like to learn more operational details, please be in touch. We are eager to see more programs like this at other centers, along with the case studies that will emerge.